These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 24239768)

  • 21. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
    Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
    Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular targets of FTY720 (fingolimod).
    Pitman MR; Woodcock JM; Lopez AF; Pitson SM
    Curr Mol Med; 2012 Dec; 12(10):1207-19. PubMed ID: 22834825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central effects of fingolimod.
    Cruz VT; Fonseca J
    Rev Neurol; 2014 Aug; 59(3):121-8. PubMed ID: 25030072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
    Kihara A; Igarashi Y
    Biochim Biophys Acta; 2008 Sep; 1781(9):496-502. PubMed ID: 18555808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
    Hu Y; Lee X; Ji B; Guckian K; Apicco D; Pepinsky RB; Miller RH; Mi S
    Mol Cell Neurosci; 2011 Sep; 48(1):72-81. PubMed ID: 21740973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion.
    Hofmann U; Burkard N; Vogt C; Thoma A; Frantz S; Ertl G; Ritter O; Bonz A
    Cardiovasc Res; 2009 Jul; 83(2):285-93. PubMed ID: 19416991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Roles for lysophospholipid S1P receptors in multiple sclerosis.
    Noguchi K; Chun J
    Crit Rev Biochem Mol Biol; 2011 Feb; 46(1):2-10. PubMed ID: 20979571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
    Chun J; Brinkmann V
    Discov Med; 2011 Sep; 12(64):213-28. PubMed ID: 21955849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of sphingosine 1-phosphate modulation on immune outcomes.
    Pinschewer DD; Brinkmann V; Merkler D
    Neurology; 2011 Feb; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
    Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
    Baumruker T; Billich A; Brinkmann V
    Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
    Cannon RE; Peart JC; Hawkins BT; Campos CR; Miller DS
    Proc Natl Acad Sci U S A; 2012 Sep; 109(39):15930-5. PubMed ID: 22949658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment.
    Leo A; Citraro R; Marra R; Palma E; Paola EDD; Constanti A; De Sarro G; Russo E
    CNS Neurol Disord Drug Targets; 2017; 16(3):311-325. PubMed ID: 27823573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
    Dudek SM; Camp SM; Chiang ET; Singleton PA; Usatyuk PV; Zhao Y; Natarajan V; Garcia JG
    Cell Signal; 2007 Aug; 19(8):1754-64. PubMed ID: 17475445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morpholino Analogues of Fingolimod as Novel and Selective S1P
    Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L; Vécsei L
    Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
    Brinkmann V
    Pharmacol Ther; 2007 Jul; 115(1):84-105. PubMed ID: 17561264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S1P lyase in thymic perivascular spaces promotes egress of mature thymocytes via up-regulation of S1P receptor 1.
    Maeda Y; Yagi H; Takemoto K; Utsumi H; Fukunari A; Sugahara K; Masuko T; Chiba K
    Int Immunol; 2014 May; 26(5):245-55. PubMed ID: 24343820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting sphingosine-1-phosphate in hematologic malignancies.
    Stevenson CE; Takabe K; Nagahashi M; Milstien S; Spiegel S
    Anticancer Agents Med Chem; 2011 Nov; 11(9):794-8. PubMed ID: 21707492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.